Under the terms of the Agreement, Geron has contributed to Asterias its stem cell intellectual property, multiple lots of OPC1 drug product used in the world's first human clinical trial of hES-derived cells in subacute spinal cord injury, multiple lots of hESC manufacturing cell banks - the starting material to manufacture additional lots of OPC1 ... (more)
http://www.businesswire.com/news/home/20131001006076/en/Asterias-Biotherapeutics-Subsidiary-BioTime-Acquires-Geron%E2%80%99s-Embryonic
http://www.businesswire.com/news/home/20131001006076/en/Asterias-Biotherapeutics-Subsidiary-BioTime-Acquires-Geron%E2%80%99s-Embryonic
No comments:
Post a Comment